CHARACTERIZATION OF EARLY STAGE BREAST CANCER PATIENT MANAGEMENT IN A PRACTICE SETTING WITH THE 21-GENE BREAST CANCER ASSAY
Author(s)
Pecora A1, Waintraub S1, Choi K2, Chao C3, Rothney M4
1Regional Cancer Care Associates, Hakensack, NJ, USA, 2COTA, Inc., New York, NY, USA, 3Genomic Health, Inc., Redwood City, CA, USA, 4Genomic Health, Inc, Redwood City, CA, USA
OBJECTIVES: Patients with low risk 21-Gene Breast Cancer Assay results can safely avoid chemotherapy (CT), as has been shown in protocol-driven studies. This study’s objective was to compare, using practice management data, CT and supportive drug therapy use in a practice setting in patients who did or didn’t receive the assay. METHODS: Patients with initial visits for ER+, HER2- ESBC to the Regional Cancer Care Associates physician practice in 2009-2013 were identified using COTA, an oncology outcomes and cost tracking database. A case-control design was used to describe demographic, clinical, adjuvant CT, and supportive care therapy information for patients < 70 years. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PMD66
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Oncology